Johnson & Johnson asked for an OMS to approve the evacuation of its evacuation against COVID-19

Johnson & Johnson vra die vierde a la Morganization Mundial de la Salud (OMS) la approbacion de su vacuna contra el COVID-19 para uso de emergencia, which must help accelerate its use in all lands of the world.

The company indicates that its pharmaceutical brand -Janssen-Cilag International- sent to the UN independent international body the most recent necessary dates of the clinical trials regarding its efficacy and inoculation, completing these procedures. Obtaining a positive response, is converted into the inertial third in the approval of the organization, which has also given its good view to the developments by Pfizer and AstraZeneca and Oxford.

Approval agilizing the access to the vacancy, which requires a single dose, for the acquisition bodies of the United Nations and for decades of peace. It is also necessary for Johnson & Johnson to increase the dose of its vaccine at MECHANISM COVAX, a project approved by the OMS to guarantee the equitable access to the vacancies for a 190-square-foot and medium-sized area. And December, Johnson & Johnson reached 500 million the dose of su vacuna and COVAX in 2022..

“If we want to catch up with the pandemic, the innovations that save lives, as well as vacancies, we must be aware of all the countries,” said Dr. Paul Stoffels, Johnson & Johnson’s scientific director, in a statement.

The company will summon the vaccine to price the lucrative during the aggravated phase of the pandemic.

In addition to requiring a single dose, the J&J vaccine can be maintained during less than three months at the temperature of a normal refrigerator, which is provided with a good option for the poor and rural areas and for the lands in development that infrastructure infrastructure for the immediate release that requires other vacancies against the COVID-19.

The provisional results of an advanced phase assay with 44,000 volunteers revelation that the Johnson & Johnson vaccine was 66% effective in preventing the moderate and severe cases of COVID-19 in Latin America and 57% in South Africa, though it is an extension of a more contagious variant. In the United States, the efficiency is 72%.

The tests also indicate that the vaccine protects 85% against more severe syndromes, leaving 28 posterior patients at the injection, investigators will find out if there is a need for hospitalization or a wall. In addition, it indicates that the rate of hospitalization or death is 100%.

‘We are amazed to see that this vaccine has a good efficacy against live diseases and a sobering effect against severe diseases in all the geographical regions studied“, Agregó el Dr. Dan Barouch of the Beth Israel Deaconess Medical Center, who collaborated with Johnson & Johnson on the development.

Finally, the pharmaceutical industry will submit an emergency approval for the United States. In this case, too, the third inoculant series to start being able to be summoned in the country, considering that the Food and Drug Administration (FDA, by its seal in English) has approved Pfizer and Modern. The company informs that podrían will send 100 million doses to the United States by June and the FDA from Luz verde al Ensayo.

The best theme:

CENTURY: Johnson & Johnson sets the authorization for the emergency use of its evacuation against the COVID-19

The vacancy of a single dose of Johnson & Johnson was effective in its Phase III studies, although some dosage formulas